IMMUNE-MEDIATED HYPERTHYROIDISM

This adverse event was reported 254 times

These drugs are most commonly taken by patients reporting IMMUNE-MEDIATED HYPERTHYROIDISM:

# Drug Count
0 PEMBROLIZUMAB 156
1 CARBOPLATIN 85
2 NIVOLUMAB 78
3 IPILIMUMAB 67
4 PACLITAXEL 58
5 PACLITAXEL (AIBUMIN-BOUND) 57
6 CYCLOPHOSPHAMIDE 28
7 CYCLOPHOSPHAMIDE FOR INJECTION 28
8 CYCLOPHOSPHAMIDE INJECTION, SOLUTION 28
9 CISPLATIN 17
See all common drugs associated with IMMUNE-MEDIATED HYPERTHYROIDISM

IMMUNE-MEDIATED HYPERTHYROIDISM is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 FOSNETUPITANT AND PALONOSETRON 6 0.0050
1 NETUPITANT AND PALONOSETRON 6 0.0050
2 PEGFILGRASTIM-JMDB 2 0.0044
3 PLATINUM 1 0.0019
4 IPILIMUMAB 67 0.0015
5 PEMBROLIZUMAB 156 0.0014
6 EPIRUBICIN HYDROCHLORIDE 7 0.0011
7 SOTORASIB 3 0.0009
8 NIVOLUMAB 78 0.0008
9 CARBOPLATIN 85 0.0007
See all drugs enriched for association with IMMUNE-MEDIATED HYPERTHYROIDISM